Cargando…

Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma

BACKGROUND: PHGDH (Phosphoglycerate Dehydrogenase) is the first branch enzyme in the serine biosynthetic pathway and plays a vital role in several cancers. However, little is known about the clinical significance of PHGDH in endometrial cancer. METHODS: Clinicopathological data of endometrial cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, He, Kong, Weimin, Zhao, Xiaoling, Xie, Yunkai, Luo, Dan, Chen, Shuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942409/
https://www.ncbi.nlm.nih.gov/pubmed/36803157
http://dx.doi.org/10.1186/s12920-023-01463-5
_version_ 1784891494017007616
author Zhang, He
Kong, Weimin
Zhao, Xiaoling
Xie, Yunkai
Luo, Dan
Chen, Shuning
author_facet Zhang, He
Kong, Weimin
Zhao, Xiaoling
Xie, Yunkai
Luo, Dan
Chen, Shuning
author_sort Zhang, He
collection PubMed
description BACKGROUND: PHGDH (Phosphoglycerate Dehydrogenase) is the first branch enzyme in the serine biosynthetic pathway and plays a vital role in several cancers. However, little is known about the clinical significance of PHGDH in endometrial cancer. METHODS: Clinicopathological data of endometrial cancer were downloaded from the Cancer Genome Atlas database (TCGA). First, the expression of PHGDH in pan-cancer was investigated, as well as the expression and prognostic value of PHGDH in endometrial cancer. The effect of PHGDH expression on the prognosis of endometrial cancer was analyzed by Kaplan-Meier plotter and Cox regression. The relationship between PHGDH expression and clinical characteristics of endometrial cancer was investigated by logistic regression. Receiver operating characteristic (ROC) curves and nomograms were developed. Possible cellular mechanisms were explored using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, the Gene Ontology (GO), and gene set enrichment analysis (GSEA). Finally, TIMER and CIBERSORT were used to analyze the relationship between PHGDH expression and immune infiltration. CellMiner™ was used to analyze the drug sensitivity of PHGDH. RESULTS: The results showed that PHGDH expression was significantly higher in endometrial cancer tissues than in normal tissues at mRNA and protein levels. Kaplan-Meier survival curves showed that patients in the high expression group had shorter overall survival (OS) and disease free survival (DFS) than patients in the low PHGDH expression group. Multifactorial COX regression analysis further supported that high PHGDH expression was an independent risk factor associated with prognosis in patients with endometrial cancer. The results showed estrogen response, mTOR, K-RAS, and epithelial mesenchymal transition (EMT) were differentially elevated in the high-expression group of the PHGDH group. CIBERSORT analysis showed that PHGDH expression is related to the infiltration of multiple immune cells. When PHGDH is highly expressed, the number of CD8(+)T cells decreases. CONCLUSION: PHGDH plays a vital role in the development of endometrial cancer, which is related to tumor immune infiltration, and can be used as an independent diagnostic and prognostic marker for endometrial cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-023-01463-5.
format Online
Article
Text
id pubmed-9942409
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-99424092023-02-22 Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma Zhang, He Kong, Weimin Zhao, Xiaoling Xie, Yunkai Luo, Dan Chen, Shuning BMC Med Genomics Research BACKGROUND: PHGDH (Phosphoglycerate Dehydrogenase) is the first branch enzyme in the serine biosynthetic pathway and plays a vital role in several cancers. However, little is known about the clinical significance of PHGDH in endometrial cancer. METHODS: Clinicopathological data of endometrial cancer were downloaded from the Cancer Genome Atlas database (TCGA). First, the expression of PHGDH in pan-cancer was investigated, as well as the expression and prognostic value of PHGDH in endometrial cancer. The effect of PHGDH expression on the prognosis of endometrial cancer was analyzed by Kaplan-Meier plotter and Cox regression. The relationship between PHGDH expression and clinical characteristics of endometrial cancer was investigated by logistic regression. Receiver operating characteristic (ROC) curves and nomograms were developed. Possible cellular mechanisms were explored using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, the Gene Ontology (GO), and gene set enrichment analysis (GSEA). Finally, TIMER and CIBERSORT were used to analyze the relationship between PHGDH expression and immune infiltration. CellMiner™ was used to analyze the drug sensitivity of PHGDH. RESULTS: The results showed that PHGDH expression was significantly higher in endometrial cancer tissues than in normal tissues at mRNA and protein levels. Kaplan-Meier survival curves showed that patients in the high expression group had shorter overall survival (OS) and disease free survival (DFS) than patients in the low PHGDH expression group. Multifactorial COX regression analysis further supported that high PHGDH expression was an independent risk factor associated with prognosis in patients with endometrial cancer. The results showed estrogen response, mTOR, K-RAS, and epithelial mesenchymal transition (EMT) were differentially elevated in the high-expression group of the PHGDH group. CIBERSORT analysis showed that PHGDH expression is related to the infiltration of multiple immune cells. When PHGDH is highly expressed, the number of CD8(+)T cells decreases. CONCLUSION: PHGDH plays a vital role in the development of endometrial cancer, which is related to tumor immune infiltration, and can be used as an independent diagnostic and prognostic marker for endometrial cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12920-023-01463-5. BioMed Central 2023-02-20 /pmc/articles/PMC9942409/ /pubmed/36803157 http://dx.doi.org/10.1186/s12920-023-01463-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, He
Kong, Weimin
Zhao, Xiaoling
Xie, Yunkai
Luo, Dan
Chen, Shuning
Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma
title Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma
title_full Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma
title_fullStr Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma
title_full_unstemmed Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma
title_short Comprehensive analysis of PHGDH for predicting prognosis and immunotherapy response in patients with endometrial carcinoma
title_sort comprehensive analysis of phgdh for predicting prognosis and immunotherapy response in patients with endometrial carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9942409/
https://www.ncbi.nlm.nih.gov/pubmed/36803157
http://dx.doi.org/10.1186/s12920-023-01463-5
work_keys_str_mv AT zhanghe comprehensiveanalysisofphgdhforpredictingprognosisandimmunotherapyresponseinpatientswithendometrialcarcinoma
AT kongweimin comprehensiveanalysisofphgdhforpredictingprognosisandimmunotherapyresponseinpatientswithendometrialcarcinoma
AT zhaoxiaoling comprehensiveanalysisofphgdhforpredictingprognosisandimmunotherapyresponseinpatientswithendometrialcarcinoma
AT xieyunkai comprehensiveanalysisofphgdhforpredictingprognosisandimmunotherapyresponseinpatientswithendometrialcarcinoma
AT luodan comprehensiveanalysisofphgdhforpredictingprognosisandimmunotherapyresponseinpatientswithendometrialcarcinoma
AT chenshuning comprehensiveanalysisofphgdhforpredictingprognosisandimmunotherapyresponseinpatientswithendometrialcarcinoma